SCHEMBL5357199

SCHEMBL5357199

O=C1C(=Nc2cc(F)cc(F)c2)c2ccccc2N1c1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 8/20 0.53
HTR4 Q13639 1/20 0.53
MAPT P10636 5/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 1/20 0.41
ACE P12821 2/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
TTR P02766 1/20 0.41
NR1H3 Q13133 1/20 0.41
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ALDH1A1 P00352 2/20 0.39
CES2 O00748 1/20 0.39
BCHE P06276 1/20 0.39
GAA P10253 1/20 0.39
CES1 P23141 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357195 1.00 GALR3 (0.53) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL8360397 0.85 GALR3 (0.50) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL8358674 0.82 NR1H3 (0.44) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL8360408 0.81 GALR3 (0.48) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL8250355 0.81 TTR (0.61) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL8253729 0.81 GALR3 (0.57) GALR3HTR4MAPTKMT2ATTR
SCHEMBL12852971 0.81 GALR3 (0.60) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL5356416 0.81 GALR3 (0.56) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL917339 0.81 GALR3 (0.48) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL917340 0.81 GALR3 (0.48) GALR3HTR4MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166635-B2 3-imino-2-indolones for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2007-01-23 US disclosed
US-7166635-B2 3-imino-2-indolones for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2007-01-23 US disclosed
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety SYNAPTIC PHARMACEUTICAL CORPORATION 2005-07-07 US disclosed
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety SYNAPTIC PHARMACEUTICAL CORPORATION 2005-07-07 US disclosed
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 GALR3 1/4885HTR4 17/4885MAPT 2743/4885
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety GALR3, GALR2, GALR1 GALR3 1/4885HTR4 13/4885MAPT 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.